Despite President Biden omitting prescription drug price controls from his American Families Act, lawmakers in Congress are forging ahead with bill H.R. 3, their plan to put the government in charge of prescription drugs.
While a government plan to control drug prices may sound appealing, such a takeover would leave patients worse off by cutting off access to the life-saving drugs and treatments they depend on.
It would also stifle innovation, leading to fewer medical breakthroughs and killing jobs in the science field. The president’s decision to leave this misguided idea out of his plan is a clear signal that Congress should walk away from it, too.
Instead of price caps, lawmakers should give Americans a personal option that brings down drug prices and boosts access to prescription medicines by increasing competition, expanding patient choice and control, and promoting innovation.